Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Total Non-Current Liabilities (2020 - 2025)

SAB Biotherapeutics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $15.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 32.47% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $15.7 million, up 32.47%, while the annual FY2025 figure was $15.7 million, 32.47% up from the prior year.
  • Total Non-Current Liabilities reached $15.7 million in Q4 2025 per SABSW's latest filing, down from $16.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $31.9 million in Q4 2021 to a low of $4.3 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $15.2 million, with a median of $15.2 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: surged 466.41% in 2022, then plummeted 41.17% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $31.9 million in 2021, then plummeted by 38.73% to $19.5 million in 2022, then decreased by 23.86% to $14.9 million in 2023, then fell by 20.39% to $11.8 million in 2024, then surged by 32.47% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Total Non-Current Liabilities are $15.7 million (Q4 2025), $16.0 million (Q3 2025), and $16.1 million (Q2 2025).